Dr. Is In Sessions

Monday, May 2, 2022

11:45 AM – 12:45 PM 3rd Floor and 7th Floor View Here

Dr. Is In

Understanding long-term Gene and Cell Therapy investment complexities requires a keen awareness of where the science and the markets are headed. That’s why “The Doctor is In” in these updates on the latest GCT technologies. Presented by Mass General Brigham clinicians and innovators from the front lines of care, the sessions are co-hosted by expert analysts from Bank of America and include interactive discussion and Q&A.

Gene and Epigenetic Editing in the Development of Treatment for Deafness

11:45 AM – 12:45 PM View Here

In this session, Dr. Edge will discuss how deafness is treated by drugs and gene editing approaches using targets discovered in cochlear organoids.
Moderator:
Geoff Meacham, PhD
Managing Director, Global Research, BofA Securities
Panelist:
Albert Edge, PhD
Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear
Single Gene Correction in the Brain: Delivering Where it Matters Most

11:45 AM – 12:45 PM View Here

In this session, Dr. Eichler will discuss the impact of gene defects across the lifespan and how timing and delivery of new genetic therapies is transforming the field of neurogenetics.
Panelist:
Florian Eichler, MD
Director, Center for Rare Neurological Diseases, MGH

Associate Professor of Neurology, HMS
Repair, Replace, Regrow: The Advancement of Regenerative Medicine

11:45 AM – 12:45 PM View Here

In this session, hear from experts in their field as they discuss the need and importance of regenerative medicine for the advancement in the treatment of diseases such as diabetes, kidney disease and blood disorders.
Moderator:
Jason Zemansky, PhD
Vice President, Global Research, BofA Securities
Panelist:
Joseph Bonventre, MD, PhD
Chief, Division of Renal Medicine, BWH

Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
David Scadden, MD
Director, Center for Regenerative Medicine, MGH

Gerald and Darlene Jordan Professor of Medicine, HMS
Smart Materials: Non-viral Vectors for Gene Therapy

11:45 AM – 12:45 PM View Here

In this session, Dr. Artzi will share how an integrative approach of combining materials science, chemistry, imaging, and biology enables targeted delivery of gene therapy.
Moderator:
Alec Stranahan, PhD
Vice President, Equity Research, BofA Securities
Panelist:
Natalie Artzi, PhD
Assistant Professor of Medicine, HMS
Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge

11:45 AM – 12:45 PM View Here

In this session, Drs. Robert Green and Adam Shaywitz will discuss how the early detection and prevention of rare diseases is imminent and represents an enormous public health opportunity.
Moderator:
Jason Gerberry
Managing Director, Global Research, BofA Securities
Panelists:
Robert Green, MD
Director, Genomes2People Research Program, BWH

Professor of Medicine, HMS
Adam Shaywitz, MD, PhD
CMO, BridgeBio Gene Therapy
Leveraging Novel Mechanisms for Accelerated Vaccine and Immunotherapy Development

11:45 AM – 12:45 PM View Here

In this session, Dr. Poznansky will share how research and development of vaccines and immunotherapy are safely accelerated from research lab to the patient leveraging novel mechanisms.
Moderator:
Alexandria Hammond, PhD
Associate, Global Research, BofA Securities
Panelist:
Mark Poznansky, MD, PhD
Director, Vaccine and Immunotherapy Center, MGH

Professor of Medicine, HMS

WMIF Main Site

2023 Event Site

Dr. Is In Sessions

Dr. Is In Sessions

Gene and Epigenetic Editing in the Development of Treatment for Deafness

Single Gene Correction in the Brain: Delivering Where it Matters Most

Repair, Replace, Regrow: The Advancement of Regenerative Medicine

Smart Materials: Non-viral Vectors for Gene Therapy

Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge

Leveraging Novel Mechanisms for Accelerated Vaccine and Immunotherapy Development